Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors.

Hepatitis B virus (HBV) ribonuclease H (RNaseH) inhibitors are a potent class of antivirals that prevent degradation of the viral pregenomic RNA during reverse transcription and block formation of mature HBV DNAs. Development of HBV RNaseH inhibitors is entering advanced preclinical analyses. To ens...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniel P Bradley, Caleb J Valkner, Qilan Li, Makafui Gasonoo, Marvin J Meyers, Georgia-Myrto Prifti, Dimitrios Moianos, Grigoris Zoidis, Adam Zlotnick, John E Tavis
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-02-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1012920
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849717826975170560
author Daniel P Bradley
Caleb J Valkner
Qilan Li
Makafui Gasonoo
Marvin J Meyers
Georgia-Myrto Prifti
Dimitrios Moianos
Grigoris Zoidis
Adam Zlotnick
John E Tavis
author_facet Daniel P Bradley
Caleb J Valkner
Qilan Li
Makafui Gasonoo
Marvin J Meyers
Georgia-Myrto Prifti
Dimitrios Moianos
Grigoris Zoidis
Adam Zlotnick
John E Tavis
author_sort Daniel P Bradley
collection DOAJ
description Hepatitis B virus (HBV) ribonuclease H (RNaseH) inhibitors are a potent class of antivirals that prevent degradation of the viral pregenomic RNA during reverse transcription and block formation of mature HBV DNAs. Development of HBV RNaseH inhibitors is entering advanced preclinical analyses. To ensure the mechanism of action was fully understood, we defined the effects of RNaseH inhibitors on other steps of HBV replication. Some N-hydroxypyridinedione (HPD) HBV RNaseH inhibitors significantly reduced accumulation of capsids in HBV-replicating cells. A representative HPD 1466, with a 50% effective concentration against HBV replication of 0.25 µM, decreased capsid and core protein accumulation by 50-90% in HepDES19 and HepG2.2.15 cells. Surprisingly, 1466 did not affect pregenomic RNA encapsidation, demonstrating a specific effect on empty capsids. HBV genomic replication was not necessary for 1466's inhibitory effect as it decreased capsid accumulation in cells transfected with replication-deficient mutants blocking pgRNA encapsidation (Δ-bulge), DNA synthesis (YMHA), and RNaseH (D702A) activities. 1466 also decreased capsid and core protein accumulation in cells transfected with a core protein expression plasmid, indicating that other HBV products are unneeded. 1466 reduced initial capsid assembly rates in biochemical assembly reactions employing purified core protein (Cp149), demonstrating a specific effect on HBV core protein. We conclude that the bimodal HPD HBV RNaseH inhibitor 1466 is the prototypic member of a new class of capsid assembly modulators (CAM) that inhibits capsid assembly rather than accelerating it, as all other CAM classes do. We propose that this class be called CAM-I, for CAM-inhibitor. These results lay the foundation for identifying bimodal HBV antivirals targeting the RNaseH and capsid assembly.
format Article
id doaj-art-feac6a4a27174b17ade952d7e33ff13c
institution DOAJ
issn 1553-7366
1553-7374
language English
publishDate 2025-02-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Pathogens
spelling doaj-art-feac6a4a27174b17ade952d7e33ff13c2025-08-20T03:12:32ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742025-02-01212e101292010.1371/journal.ppat.1012920Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors.Daniel P BradleyCaleb J ValknerQilan LiMakafui GasonooMarvin J MeyersGeorgia-Myrto PriftiDimitrios MoianosGrigoris ZoidisAdam ZlotnickJohn E TavisHepatitis B virus (HBV) ribonuclease H (RNaseH) inhibitors are a potent class of antivirals that prevent degradation of the viral pregenomic RNA during reverse transcription and block formation of mature HBV DNAs. Development of HBV RNaseH inhibitors is entering advanced preclinical analyses. To ensure the mechanism of action was fully understood, we defined the effects of RNaseH inhibitors on other steps of HBV replication. Some N-hydroxypyridinedione (HPD) HBV RNaseH inhibitors significantly reduced accumulation of capsids in HBV-replicating cells. A representative HPD 1466, with a 50% effective concentration against HBV replication of 0.25 µM, decreased capsid and core protein accumulation by 50-90% in HepDES19 and HepG2.2.15 cells. Surprisingly, 1466 did not affect pregenomic RNA encapsidation, demonstrating a specific effect on empty capsids. HBV genomic replication was not necessary for 1466's inhibitory effect as it decreased capsid accumulation in cells transfected with replication-deficient mutants blocking pgRNA encapsidation (Δ-bulge), DNA synthesis (YMHA), and RNaseH (D702A) activities. 1466 also decreased capsid and core protein accumulation in cells transfected with a core protein expression plasmid, indicating that other HBV products are unneeded. 1466 reduced initial capsid assembly rates in biochemical assembly reactions employing purified core protein (Cp149), demonstrating a specific effect on HBV core protein. We conclude that the bimodal HPD HBV RNaseH inhibitor 1466 is the prototypic member of a new class of capsid assembly modulators (CAM) that inhibits capsid assembly rather than accelerating it, as all other CAM classes do. We propose that this class be called CAM-I, for CAM-inhibitor. These results lay the foundation for identifying bimodal HBV antivirals targeting the RNaseH and capsid assembly.https://doi.org/10.1371/journal.ppat.1012920
spellingShingle Daniel P Bradley
Caleb J Valkner
Qilan Li
Makafui Gasonoo
Marvin J Meyers
Georgia-Myrto Prifti
Dimitrios Moianos
Grigoris Zoidis
Adam Zlotnick
John E Tavis
Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors.
PLoS Pathogens
title Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors.
title_full Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors.
title_fullStr Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors.
title_full_unstemmed Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors.
title_short Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors.
title_sort discovery of bimodal hepatitis b virus ribonuclease h and capsid assembly inhibitors
url https://doi.org/10.1371/journal.ppat.1012920
work_keys_str_mv AT danielpbradley discoveryofbimodalhepatitisbvirusribonucleasehandcapsidassemblyinhibitors
AT calebjvalkner discoveryofbimodalhepatitisbvirusribonucleasehandcapsidassemblyinhibitors
AT qilanli discoveryofbimodalhepatitisbvirusribonucleasehandcapsidassemblyinhibitors
AT makafuigasonoo discoveryofbimodalhepatitisbvirusribonucleasehandcapsidassemblyinhibitors
AT marvinjmeyers discoveryofbimodalhepatitisbvirusribonucleasehandcapsidassemblyinhibitors
AT georgiamyrtoprifti discoveryofbimodalhepatitisbvirusribonucleasehandcapsidassemblyinhibitors
AT dimitriosmoianos discoveryofbimodalhepatitisbvirusribonucleasehandcapsidassemblyinhibitors
AT grigoriszoidis discoveryofbimodalhepatitisbvirusribonucleasehandcapsidassemblyinhibitors
AT adamzlotnick discoveryofbimodalhepatitisbvirusribonucleasehandcapsidassemblyinhibitors
AT johnetavis discoveryofbimodalhepatitisbvirusribonucleasehandcapsidassemblyinhibitors